You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 3, 2024

Oliceridine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for oliceridine and what is the scope of patent protection?

Oliceridine is the generic ingredient in one branded drug marketed by Trevena and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Oliceridine has fifty-one patent family members in twenty-three countries.

One supplier is listed for this compound.

Summary for oliceridine
International Patents:51
US Patents:5
Tradenames:1
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 32
Clinical Trials: 5
Patent Applications: 97
What excipients (inactive ingredients) are in oliceridine?oliceridine excipients list
DailyMed Link:oliceridine at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for oliceridine
Generic Entry Date for oliceridine*:
Constraining patent/regulatory exclusivity:
Dosage:
SOLUTION;INTRAVENOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for oliceridine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of TennesseePhase 4
Trevena Inc.Phase 4
The Cleveland ClinicPhase 3

See all oliceridine clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for oliceridine

US Patents and Regulatory Information for oliceridine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-003 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Trevena OLINVYK oliceridine SOLUTION;INTRAVENOUS 210730-001 Oct 30, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for oliceridine

Country Patent Number Title Estimated Expiration
South Korea 20190072665 오피오이드 수용체 리간드와 그 용도 및 제조방법 (Opioid Receptor Ligands and Methods of Using and Making Same) ⤷  Sign Up
South Korea 101991327 ⤷  Sign Up
Israel 272165 ליגנדים של קולטן אופיואיד ושיטות לשימוש בהם ולהכנתם (Opioid receptor ligands and methods of using and making same) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.